Tabuk Pharma and Althera Laboratories Announce Strategic Licensing and Supply Agreement for Advanced Type 2 Diabetes Therapy in MENA
Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region. This collaboration reinforces Tabuk Pharma’s commitment
Tabuk Pharma Signs Strategic Agreements with Local Content and Government Procurement Authority at Global Health Exhibition 2025
As part of the Global Health Exhibition 2025, Tabuk Pharma signed two strategic agreements with the Local Content and Government Procurement Authority, marking a significant milestone in strengthening pharmaceutical lo
Tabuk Pharma Signs Exclusive License and Supply Agreement with Hanmi Pharmaceutical for Rolontis® (Eflapegrastim) in Saudi Arabia and MENA
Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis® (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Ara
Tabuk Pharmaceuticals Announces Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20, an innovative First in class arginine degradation platform for hard-to-treat cancers in the Kingdom of Saudi Arabia and GCC Region.
Strategic Collaboration to Address Critical Healthcare Needs and Expand Access to Life-Changing Treatments Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a l